HealthQuill Pharma
Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.
Drugs Health Pharma

Roche to acquire US-based Poseida Therapeutics for $1.5 billion

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

Read More
Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.
Drugs Health Pharma

Cassava’s disputed Alzheimer’s drug flops in end-stage trials

Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.

Read More
Negotiators at a global climate conference signed a $300 billion-a-year deal to finance emissions reduction — that developing nations say falls way short of their expectations.
Climate Health Pharma

Global warming on backburner; vexed financing deal sees light at COP29 

Global representatives at a climate conference signed a $300 billion-a-year deal to finance emissions reductions — a move developing nations say falls way.

Read More
A sedentary lifestyle of more than 10.6 hours a day increases heart disease by up to 60%, according to a study by Mass General Brigham researchers.
Health Medical Pharma

Sitting for 10.6 hours a day increases heart disease risk by 60%

A sedentary lifestyle of more than 10.6 hours a day increases heart disease by up to 60%, according to a study by Mass.

Read More
The WHO says close to 18 million people die due to cardiovascular disease every year out of which maximum deaths are due to SCA. Heart attacks occur when there is a blockage in one or more of the arteries to the heart, preventing the heart from receiving enough oxygen-rich blood.
Pharma

Eli Lilly’s pill for genetic high cholesterol cuts risk by 86% in trial 2

HQ Team November 19, 2024: Eli Lilly announced promising results from its Phase 2 clinical trial of muvalaplin, an oral medication designed to.

Read More
Measles cases worldwide have risen 20% year-on-year in 2023 to about 10.3 million due to inadequate access to vaccines, according to new estimates from the World Health Organization.
Drugs Health Pharma

Measles cases surge worldwide, access to vaccine is ‘inadequate’: WHO

Measles cases worldwide have risen 20% year-on-year in 2023 to about 10.3 million due to inadequate access to vaccines, according to new estimates.

Read More
GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high
Drugs Health Pharma

Global diabetic population rose fourfold to 828 million in 2022

The global diabetic population has risen fourfold to 828 million during the last three decades, with more than a quarter living in India,.

Read More
ARS Pharmaceuticals, a US-based biopharmaceutical company, got the nation’s drug regulator’s approval for a nasal spray to treat allergic reactions in adult and paediatric patients.
Pharma

Danish Pharma ALK pays ARS $145m for Neffy nasal spray licensing deal

HQ Team November 13, 2024: ALK-Abelló, the Danish pharma company has acquired exclusive rights to Neffy (epinephrine nasal spray) from ARS Pharmaceuticals for.

Read More
Novovax Inc., will soon start enrollment for end-stage trials of its Covid-19-Influenza vaccine and stand-alone influenza jab following a nod from the US drug regulator.
Drugs Health Pharma

US drug regulator removes clinical hold on Novavax’s vaccines

Novovax Inc., will soon start enrollment for end-stage trials of its Covid-19-Influenza vaccine and stand-alone influenza jab following a nod from the US.

Read More
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Health Pharma

AstraZeneca to invest $3.5 billion in the US to expand global footprint

Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of.

Read More